Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07XJM
|
||||
| Former ID |
DAP001118
|
||||
| Drug Name |
Dicyclomine
|
||||
| Synonyms |
Atumin; Bentomine; Bentylol; Dicicloverina; Dicycloverin; Dicycloverine; Dicycloverinum; Dicymine; Diocyl; Dyspas; Formulex; Mamiesan; Merbentyl; Procyclomin; Sawamin; Spasmoban; Wyovin; Bentyl hydrochloride; Bentylol hydrochloride; Dicyclomine Hcl; Dicycloverin hydrochloride; Diethylaminocarbethoxybicyclohexyl hydrochloride; Diocyl hydrochloride; Kolantyl hydrochloride; Wyovin hydrochloride; GU8471000; Bentyl (TN); Bentylol (TN); Byclomine (TN); Di-syntramine; Dibent (TN); Dicicloverina [INN-Spanish]; Dicycloverine (INN); Dicycloverine [INN:BAN]; Dicycloverinum [INN-Latin]; Dicymine (TN); Dilomine (TN); Formulex (TN); Lomine (TN); Merbentyl (TN); Oxityl-P; Beta-Diethylaminoethyl 1-cyclohexylcyclohexanecarboxylate hydrochloride; Di-Spaz (TN); J.L. 998; Beta-Diethylaminoethyl-1-cyclohexylhexahydrobenzoate hydrochloride; Bicyclohexyl-1-carbonsaeure-2'diethylaminoethylester; [Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester hydrochloride; Cyclohexanecarboxylic acid, 1-cyclohexyl-, 2-(diethylamino)ethyl ester; [1,1'-Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester; (1,1'-Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; (BICYCLOHEXYL)-1-CARBOXYLIC ACID, 2-(DIETHYLAMINO)ETHYL ESTER, HYDROCHLORIDE; (Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; 1-Cyclohexylcyclohexanecarboxylic acid 2-(diethylamino)ethyl ester; 2-(diethylamino)ethyl 1,1'-bi(cyclohexyl)-1-carboxylate; 2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate hydrochloride
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Functional bowel syndrome; Irritable bowel syndrome [ICD10:K58] | Approved | [1] | ||
| Therapeutic Class |
Anticholinergic Agents
|
||||
| Company |
Peckforton Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H35NO2
|
||||
| InChI |
InChI=1S/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3
|
||||
| InChIKey |
CURUTKGFNZGFSE-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 77-19-0
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9166, 579063, 5394320, 7979069, 8151936, 10535471, 11111098, 11112188, 11335337, 11360576, 11363828, 11366390, 11368952, 11371495, 11374196, 11377114, 11461548, 11466076, 11467196, 11484176, 11485832, 11488406, 11490204, 11492324, 11494748, 15048766, 29222188, 46505371, 47440119, 47662128, 47662129, 48034974, 48110323, 48184864, 48259084, 48334352, 48415886, 49698855, 49957700, 50065186, 50100226, 50104289, 57321573, 80483160, 85209403, 85789477, 90341021, 96024517, 99313632, 103318016
|
||||
| SuperDrug ATC ID |
A03AA07
|
||||
| SuperDrug CAS ID |
cas=000077190
|
||||
| Target and Pathway | |||||
| Target(s) | Muscarinic acetylcholine receptor M1 | Target Info | Antagonist | [2], [3] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| PI3K-Akt signaling pathway | |||||
| Cholinergic synapse | |||||
| Regulation of actin cytoskeleton | |||||
| PANTHER Pathway | Alzheimer disease-amyloid secretase pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||||
| Reactome | Muscarinic acetylcholine receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| Regulation of Actin Cytoskeleton | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Secretion of Hydrochloric Acid in Parietal Cells | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | Fustin flavonoid attenuates beta-amyloid (1-42)-induced learning impairment. J Neurosci Res. 2009 Jun 16. | ||||
| REF 3 | Characterization of undifferentiated muscarinic thyroid cells in Fisher rats.. Endocrinol Nutr. 2009 Mar;56(3):106-11. Epub 2009 May 18. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.